C5001001
Are You Eligible?The purpose of this study is to learn about the effects of the study drug (PF-07868489) and to test the safety (the impact of the study drug on your body) of the study drug while you remain on your regular medications for the treatment of Pulmonary Arterial Hypertension.
Research Objectives
Status
Recruitment
Total participants required
Study location
Study type
Patient group
About this clinical trial
Pfizer Inc. is conducting a study of an investigational drug, called PF-0786849, for the treatment of PAH. The study has two parts. In Part A, the study drug was tested in healthy adults and was generally well tolerated with no safety concerns reported. The study is now in Part B, which involves people diagnosed with PAH.
In this part, participants will receive multiple doses of PF-0786849. The medication is given as two small injections under the skin—either in the abdomen, thigh, or back of the arms. Some participants will receive a placebo (a substance that looks like the study drug but has no active ingredients) so researchers can compare the effects and determine how well the study drug works.
The goal is to better understand how PF-0786849 affects people with PAH and whether it could be a safe and effective treatment option in the future.
Trial information – https://clinicaltrials.gov/study/NCT06137742
Eligibility
- Adults aged 18 years and above
- Diagnosed with Pulmonary Arterial Hypertension
- Possess a BMI between 16 to 35 kg/m2
Lead investigator
- Dr John Feenstra
Clinical trial coordinator
- Bronwen Field
Technical title
A Phase 1 / 2, Randomized, Double-Blind, Placebo Controlled Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of Single Escalating Doses of Pf-07868489 in Healthy Adult Participants and, additionally, Clinical Activity of Repeat Doses In Participants with Pulmonary Arterial Hypertension
Register your interest
If you would like more information about this clinical trial, please complete the contact form below.